XOMA Corp (NASDAQ:XOMA)’s shares jumped 6.56% to $4.91. The company on May 7 announced its operational highlights and financial results for the first quarter ended March 31, 2014. The company recorded total revenues of $3.4 million for the three months ended March 31, 2014, compared with $9.5 million during the corresponding period of 2013, which included a $3.9 million milestone payment from SERVIER related to a product development program that XOMA subsequently transferred to Symplmed. For the first quarter ended March 31, 2014, XOMA had a net loss of $4.7 million, or $0.04 per share, compared with a net loss of $24.9 million, or $0.30 per share, in the quarter ended March 31, 2013. XOMA Corp (NASDAQ:XOMA), weekly performance is 19.26%. On last trading day company shares ended up $4.83. Analysts mean target price for the company is $9.13. XOMA Corp (NASDAQ:XOMA), distance from 50-day simple moving average (SMA50) is 13.25%.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), saw a large decline in short interest in April. As of April 30th, there was short interest totalling 18,661,854 shares, a decline of 9.9% from the April 15th total of 20,716,430 shares, Stock Ratings Network reports. Approximately 31.5% of the company’s stock are sold short. Based on an average daily volume of 1,068,926 shares, the short-interest ratio is presently 17.5 days. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), advanced 1.49% in last trading session and ended the day on $4.08. ZIOP, return on assets is -102.80%. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), quarterly performance is -0.49%.
Neuralstem, Inc. (NYSEMKT:CUR), published a new blog post on the Company’s website which was republished on TheChairmansBlog.com, written by the Company’s President and CEO, Richard Garr. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. Neuralstem, Inc. (NYSEMKT:CUR), shares moved down 4.43% in last trading session and was closed at $4.31, while trading in range of $4.23 – 4.61. Neuralstem, Inc. (NYSEMKT:CUR), year to date (YTD) performance is 48.11%.
On May 31, 2014, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), ended the last trading day at $1.10. Company weekly volatility is calculated as 5.77% and price to cash ratio as 0.65. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), showed a positive weekly performance of 0.92%.
On May 29, 2014, 22nd Century Group Inc (NYSEMKT:XXII), announced that its wholly-owned holding company, Goodrich Tobacco Company LLC, has entered into an agreement with Poland based Orion, which is also a cigarette manufacturer. The letter of intent exchanged between the two companies is with respect to 22nd Century’s plan to give Orion, a contract to manufacture and distribute its patented tobacco products across the European continent. 22nd Century Group Inc (NYSEMKT:XXII), weekly performance is 17.97%. On last trading day company shares ended up $3.48. Analysts mean target price for the company is $9.00. 22nd Century Group Inc (NYSEMKT:XXII), distance from 50-day simple moving average (SMA50) is 26.87%.